Global Small Molecule Innovator API CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Small Molecule Innovator API CDMO Market is presumed to reach the market size of nearly USD 57.39 Billion by 2032 from USD 30.16 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule innovator api cdmo. The growth and trends of small molecule innovator api cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule innovator api cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Stage Type

Preclinical
Clinical (Phase I, Phase II, Phase III)
Commercial

By Customer Type

Pharmaceutical (Small, Medium, Large)
Biotechnology (Small, Medium, Large)

By Therapeutic Area

Cardiovascular Diseases
Oncology
Respiratory Disorders
Neurology
Metabolic Disorders
Infectious Diseases
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Innovator API CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Innovator API CDMO market include Lonza Group Ltd., Novo Holdings (Catalent Inc.), Thermo Fisher Scientific, Inc., Siegfried Holding AG, Recipharm AB, CordenPharma International, Samsung Biologics, LabCorp, Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Jubilant Life Sciences (Jubilant Biosys Ltd.), WuXi AppTec Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114302

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SMALL MOLECULE INNOVATOR API CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Stage Type
- 3.7.2 Market Attractiveness Analysis By Customer Type
- 3.7.3 Market Attractiveness Analysis By Therapeutic Area
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY STAGE TYPE

5.1. Overview By Stage Type
5.2. Historical and Forecast Data
5.3. Analysis By Stage Type
5.4. Preclinical Historic and Forecast Sales By Regions
5.5. Clinical (Phase I, Phase II, Phase III) Historic and Forecast Sales By Regions
5.6. Commercial Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY CUSTOMER TYPE

6.1. Overview By Customer Type
6.2. Historical and Forecast Data
6.3. Analysis By Customer Type
6.4. Pharmaceutical (Small, Medium, Large) Historic and Forecast Sales By Regions
6.5. Biotechnology (Small, Medium, Large) Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY THERAPEUTIC AREA

7.1. Overview By Therapeutic Area
7.2. Historical and Forecast Data
7.3. Analysis By Therapeutic Area
7.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
7.5. Oncology Historic and Forecast Sales By Regions
7.6. Respiratory Disorders Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Metabolic Disorders Historic and Forecast Sales By Regions
7.9. Infectious Diseases Historic and Forecast Sales By Regions
7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE INNOVATOR API CDMO COMPANIES

9.1. Small Molecule Innovator API CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Lonza Group Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novo Holdings (Catalent Inc.)
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Siegfried Holding AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Recipharm AB
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. CordenPharma International
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Samsung Biologics
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. LabCorp
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Ajinomoto Bio-Pharma Services
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Piramal Pharma Solutions
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences (Jubilant Biosys Ltd.)
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. WuXi AppTec Co. Ltd.
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies